GSK to Shine Light on Raw Clinical Trial Data
By Marie Powers
Wednesday, October 17, 2012
GlaxoSmithKline plc (GSK) took extraordinary steps toward data transparency last week, disclosing plans to accelerate its "open innovation" approach to R&D by allowing researchers access to detailed patient-level data underlying clinical trials both in approved medicines and failed investigational compounds.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.